The limited armamentarium against drug-resistant Gram-negative bacilli has led to the
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa
isolates are frequent causes of serious nosocomial infections that may compromise the …

In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …

ABSTRACT β-Lactamases, the major resistance determinant for β-lactam antibiotics in Gram-
negative bacteria, are ancient enzymes whose origins can be traced back millions of years …

Pseudomonas aeruginosa is an important Gram-negative opportunistic pathogen which
causes many severe acute and chronic infections with high morbidity, and mortality rates as …

Ceftazidime-avibactam (Zavicefta®) is an intravenously administered combination of the
third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase …

Ceftolozane/tazobactam and ceftazidime/avibactam are 2 novel β-lactam/β-lactamase
combination antibiotics. The antimicrobial spectrum of activity of these antibiotics includes …

Abstract Objective Ceftazidime–avibactam (CAZ-AVI) is a novel synthetic β-lactamase
inhibitor combination. Although the combination has been available clinically for only a few …

Multidrug resistance (MDR) represents a serious global threat due to the rapid global spread
and limited antimicrobial options for treatment of difficult-to-treat (DTR) infections sustained …

Background Excesses of antibiotic resistance genes (ARGs), which are regarded as
emerging environmental pollutants, have been observed in various environments. The …